

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH SYSMEX

This announcement is made by IVD Medical Holding Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the latest information on recent developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that, on 2 November 2023, Vastec Medical Equipment (Shanghai) Co., Ltd. (“**Vastec**”), a wholly-owned subsidiary of the Company, entered into certain agreements (the “**Strategic Cooperation Agreements**”) with Sysmex Shanghai Ltd. (“**Sysmex Shanghai**”) for the parties’ strategic cooperation in relation to haemostasis products business (the “**Strategic Cooperation**”).

Having considered the 26 years of history of working together, in order to better tackle the market change in the future, Vastec and Sysmex Shanghai both agreed to enhance the parties’ cooperation and entered into the Strategic Cooperation Agreements, under which (subject to certain customary condition precedents) the parties will amend the current distribution right of Vastec, and cooperate in relation to the shareholding structure of Vastec. In particular, Vastec’s distribution right to distribute Sysmex’s haemostasis products in designated areas in the People’s Republic of China will be amended from a specified period right to a long-term right. On the other hand, Sysmex Shanghai will inject capital into and become a shareholder of Vastec, which will continue to be a subsidiary of the Company, and the Company will continue to have actual control over Vastec.

The Group’s distribution of haemostasis products is primarily conducted through Vastec and our key supplier is Sysmex Shanghai. Sysmex Shanghai is a wholly-owned subsidiary of Sysmex Corporation (“**Sysmex**”). Sysmex is a Japanese healthcare company headquartered in Kobe and established in 1968, it has the leading market share in the global haematology, haemostasis and urinalysis market (including through its alliances).

The Board believes that the Strategic Cooperation will strengthen the relationship between the Group and Sysmex, effectively maintain the supply of Sysmex's haemostasis products for Vastec's distribution and the Group's authorized distribution areas of such products under normal circumstances. The Strategic Cooperation will enable the Group and Sysmex to leverage on their respective strength, resources and expertise to continue to develop their long-term and mutually beneficial strategic relationship, accordingly the Board considers that the entering into of the Strategic Cooperation Agreements is in the interests of the Company and its shareholders as a whole.

By Order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 2 November 2023

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive Directors, namely, Ms. Yao Haiyun, Mr. Yang Zhaoxu and Mr. Sun Tao and three independent non-executive Directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.